Products
Rademikibart Biosimilar Monoclonal Antibody (IL-4Rα) for Research
Cat No.: GMP-Bios-INN-1352
Anti-IL4R/CD124 therapeutic antibody (Pre-made Rademikibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rademikibart (development code CBP 201) is a monoclonal antibody targeting IL-4 receptor alpha (IL4R). It is developed by Suzhou Connect Biopharmaceuticals for Asthma, Atopic dermatitis, Rhinosinusitis in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1352-1mg | 1mg | 3090 |
| GMP-Bios-INN-1352-10mg | 10mg | |
| GMP-Bios-INN-1352-100mg | 100mg | |
| GMP-Bios-INN-1352-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rademikibart biosimilar, Whole mAb, Anti-IL4R/CD124 Antibody: Anti-IL-4RA/CD124/IL4R/Interleukin-4 receptor subunit alpha therapeutic antibody |
| INN Name | Rademikibart |
| Target | IL4R/CD124 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Suzhou Connect Biopharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Asthma;Atopic dermatitis;Rhinosinusitis |
| Conditions Discontinued | Nasal polyps |
| Production | na |
| Development Tech | na |
